ALX Stock Recent News

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $3.31 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.55 per share a year ago.

From a fundamental standpoint, this may be a good time to invest in REITs with high yields. It's crucial to avoid mousetrap REITs with high dividend yields that may be unsustainable, as dividend cuts quickly lead to dramatic losses in share value and reduced income. This article lists 22 equity REITs in significant danger of a dividend cut within the next 12 months.

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced topline data from its Phase 2 ASPEN-06 clinical trial. The trial demonstrated clinically meaningful improvements in overall response rate and duration of response among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

PARAMUS, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on August 30, 2024 to stockholders of record on August 12, 2024.

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.

PARAMUS, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2024 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 5, 2024, before the New York Stock Exchange opens.

Office REITs have gained modestly this year, but face challenges due to the WFH trend and mounting defaults in commercial real estate loans. Alexanders, Inc. is a small-cap REIT with a portfolio of office and retail properties in New York City, facing heavy indebtedness, shrinking revenues, and reliance on a single tenant. ALX faces liquidity issues, and may need to cut dividends or dilutively issue new shares, making it a risky investment for the longer term.

There will likely be a major sell-off in REITs in the next 2-5 years. Weak REITs with messy balance sheets, weak forecasts for FFO growth, unsafe dividends, and/or overvaluation are likely to suffer the most damage in any downturn. This article focuses on three specific REITs that may be particularly vulnerable in a downturn.

ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection. Evorpacept is the main focus, showing promising activity signals in gastric cancer and urothelial carcinoma, with upcoming data updates and trials. Financially, ALXO has a reasonable cash pool to fund operations for the near term, with a runway of 5-6 quarters.

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company")  is pleased to announce that it has acquired the Blackbird Project ("Blackbird", or the "Project") in northern Saskatchewan, Canada. Blackbird consists of twelve mineral claims staked in June 2024 on behalf of the Company, giving the Project a total area of approximately 11,628 hectares (28,733 acres).